心力衰竭患者流感疫苗接种:观察性研究的系统综述与荟萃分析
结果显示,流感疫苗接种与全因死亡风险降低相关(HR=0.83;95%CI 0.76-0.91;I2=75%),但心血管死亡和全因住院的合并分析未达统计学显著性。多数结局存在严重偏倚风险,且几乎全部结局的GRADE证据质量极低。
要点
- 流感疫苗接种与心衰患者全因死亡风险降低相关,HR=0.83(95%CI 0.76-0.91)。
- 心血管死亡和全因住院的合并分析未显示统计学显著性。
- 多数结局存在严重偏倚风险,GRADE证据质量极低,需谨慎解读。
核心结论
- 流感疫苗接种与心衰患者全因死亡风险显著降低相关,但心血管死亡和全因住院的合并效应未达统计学显著性。
主要发现
- 流感疫苗接种与全因死亡风险降低相关(HR=0.83;95%CI 0.76至0.91;I2=75%)。
- 心血管死亡的合并分析(2项研究)无统计学显著性(HR=0.92,95%CI 0.73至1.15)。
- 全因住院的合并分析(2项研究)无统计学显著性(HR=1.01,95%CI 0.92至1.11)。
- 纳入研究多数结局存在严重偏倚风险,几乎全部结局的GRADE证据质量极低。
关键数值与推荐
- 全因死亡:HR=0.83(95%CI 0.76-0.91;I2=75%)。
- 心血管死亡:HR=0.92(95%CI 0.73-1.15;2项研究)。
- 全因住院:HR=1.01(95%CI 0.92-1.11;2项研究)。
临床怎么用
- 基于现有极低质量证据,流感疫苗接种可能有助于降低心衰患者全因死亡风险,临床可考虑对心衰患者推荐接种流感疫苗。
局限性
- 纳入研究多为观察性设计,多数结局存在严重偏倚风险。
- 几乎全部结局的GRADE证据质量极低,合并效应估计不确定性大。
- 心血管死亡和全因住院的合并分析仅纳入2项研究,检验效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite the progression of treatments over decades, heart failure (HF) is a disease with high morbidity, mortality and economic burden. Influenza infection is an important trigger for cardiovascular (CV) events, including HF. Influenza vaccination has been seen to reduce the risk of CV mortality in patients with coronary disease, but the effect in patients with HF is still unclear. Therefore, we conducted a systematic review to evaluate the effect of influenza vaccination in the morbimortality of patients with HF. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Health Technology Assessment and PsycINFO databases (December 2018) were searched for longitudinal studies evaluating influenza vaccination compared with a non-vaccination control group in patients with HF. The risk of bias was assessed according to the ROBINS-I tool. We performed a random-effects meta-analysis to estimate the pooled HRs with 95% CIs, and heterogeneity was evaluated using the I2 statistics. RESULTS: Six cohort studies evaluating 179 158 patients with HF were included in the meta-analysis. Influenza vaccination was associated with a lower risk of all-cause mortality (HR=0.83; 95% CI 0.76 to 0.91; I2=75%). The effect of the influenza vaccination was not statistically significant in a pooled analysis of CV mortality (HR=0.92, 95% CI 0.73 to 1.15; 2 studies) and of all-cause hospitalisations (HR=1.01, 95% CI 0.92 to 1.11; 2 studies). The majority of outcomes in the included studies had a serious risk of bias and almost all evaluated outcomes had very low Grading of Recommendation, Assessment, Development and Evaluation (GRADE) evidence. CONCLUSIONS: Influenza vaccination was associated with a significant decrease in all-cause mortality risk in patients with HF.
引用
- Rodrigues BS, David C, Costa J, et al. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart. 2019. PMID: 31444266. doi:10.1136/heartjnl-2019-315193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。